Cell Therapy
Clinical Trials
Gene Therapy
Regulatory & Standards

Overcoming Key Regulatory Issues in Cell and Gene Therapies with Reliable and Expansive Expertise

Phacilitate
30 March 2022
SHARE NOW
Emma Cheesman-Ungstrup shares her top 3 takeaways from a panel discussion moderated by Biopharma Excellence at Advanced Therapies Week 2022.

For this short interview, Emma Cheesman-Ungstrup, Director of Development Consulting and Scientific Affairs at Biopharma Excellence, describes a few of her key takeaways from a panel discussion hosted at Advanced Therapies Week 2022.

The session, titled ‘Where Are We Now and Where Are We Heading? Cell and Gene Therapy in 2022‘, included presentations from Janet Lynch Lambert from the Alliance for Regenerative Medicine, Susan Nichols from Propel Biosciences and Peter Marks from the Center for Biologics Evaluation and Research, FDA.

The speakers were then joined by Shephard Mpofu from Novartis Gene Therapies, Bruce Levine from the University of Pennsylvania and Tim Farries from Biopharma Excellence to address audience questions and discuss cell and gene therapies in 2022 as well as the the next five years, with the discussion moderated by Emma Cheesman-Ungstrup.

This interview has been produced in partnership with Biopharma Excellence. To find out more, visit: www.biopharma-excellence.com

Enjoyed this video? Join the network to access exclusive content from Advanced Therapies Week 2022 >> 


While we have you…

We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.